OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Allergy and Clinical Immunology-In Practice is 50. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach	332
A Consensus Approach to the Primary Prevention of Food Allergy Through Nutrition: Guidance from the American Academy of Allergy, Asthma, and Immunology; American College of Allergy, Asthma, and Immuno	193
Chronic Rhinosinusitis with Nasal Polyps and Asthma	190
US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema	177
Polyethylene Glycol–Induced Systemic Allergic Reactions (Anaphylaxis)	154
The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach	154
Overview of STING-Associated Vasculopathy with Onset in Infancy (SAVI) Among 21 Patients	117
Prevalence of Comorbid Asthma and Related Outcomes in COVID-19: A Systematic Review and Meta-Analysis	114
Eosinophilia in Asthma Patients Is Protective Against Severe COVID-19 Illness	114
Long-Term Therapy Response to Anti–IL-5 Biologics in Severe Asthma—A Real-Life Evaluation	112
Pediatric Asthma Health Care Utilization, Viral Testing, and Air Pollution Changes During the COVID-19 Pandemic	105
First-Dose mRNA COVID-19 Vaccine Allergic Reactions: Limited Role for Excipient Skin Testing	103
Artificial Intelligence/Machine Learning in Respiratory Medicine and Potential Role in Asthma and COPD Diagnosis	98
Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis	97
Benralizumab as a Steroid-Sparing Treatment Option in Eosinophilic Granulomatosis with Polyangiitis	89
The Pathogenesis of Chronic Spontaneous Urticaria: The Role of Infiltrating Cells	86
Drug-Induced Hypersensitivity Syndrome (DIHS)/Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS): Clinical Features and Pathogenesis	86
Anti-PEG IgE in anaphylaxis associated with polyethylene glycol	85
Clinical Relevance of Cross-Reactivity in Food Allergy	82
Defining a Severe Asthma Super-Responder: Findings from a Delphi Process	80
Emerging Causes of Drug-Induced Anaphylaxis: A Review of Anaphylaxis-Associated Reports in the FDA Adverse Event Reporting System (FAERS)	80
Biologics for Treatment of Atopic Dermatitis: Current Status and Future Prospect	80
Improving Diagnostic Accuracy in Food Allergy	79
Real-World Effectiveness of Omalizumab in Severe Allergic Asthma: A Meta-Analysis of Observational Studies	79
Biologics for the Use in Chronic Spontaneous Urticaria: When and Which	77

Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes	73
Hereditary Alpha-Tryptasemia: UK Prevalence and Variability in Disease Expression	73
Epidemiology of Chronic Rhinosinusitis: Prevalence and Risk Factors	73
Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma	68
Clinical outcomes and features of COVID-19 in patients with primary immunodeficiencies in New York City	68
Integrated Safety and Efficacy Among Patients Receiving Benralizumab for Up to 5 Years	65
Impact of Allergic Rhinitis and Asthma on COVID-19 Infection, Hospitalization, and Mortality	65
Continuous and Daily Oral Immunotherapy for Peanut Allergy: Results from a 2-Year Open-Label Follow-On Study	63
Complications of switching from anti–IL-5 or anti–IL-5R to dupilumab in corticosteroid-dependent severe asthma	62
Digital Health Technology in Asthma: A Comprehensive Scoping Review	62
Trends in hospitalizations for asthma during the COVID-19 outbreak in Japan	61
Reduction of allergic rhinitis symptoms with face mask usage during the COVID-19 pandemic	61
Cluster Analysis of Inflammatory Biomarker Expression in the International Severe Asthma Registry	61
Rhinovirus Infections and Their Roles in Asthma: Etiology and Exacerbations	60
The Prevalence of Subtypes of Type 2 Inflammation in an Unselected Population of Patients with Severe Asthma	59
COVID-19 Susceptibility in Bronchial Asthma	58
Immunological Responses and Biomarkers for Allergen-Specific Immunotherapy Against Inhaled Allergens	57
Clinical outcome, incidence, and SARS-CoV-2 infection-fatality rates in Italian patients with inborn errors of immunity	57
An Approach to the Office-Based Practice of Food Oral Immunotherapy	56
Indirect Treatment Comparison of Biologics in Chronic Rhinosinusitis with Nasal Polyps	55
Use and Interpretation of Acute and Baseline Tryptase in Perioperative Hypersensitivity and Anaphylaxis	54
Prevalence and Burden of Chronic Cough in the United States	53
Which Are the Optimal Criteria for the Diagnosis of Allergic Bronchopulmonary Aspergillosis? A Latent Class Analysis	52
Chronic Rhinosinusitis With Nasal Polyps: Quality of Life in the Biologics Era	51
Asthma and COPD Are Not Risk Factors for ICU Stay and Death in Case of SARS-CoV2 Infection	51
Geospatial Analysis of Social Determinants of Health Identifies Neighborhood Hot Spots Associated With Pediatric Intensive Care Use for Life-Threatening Asthma	50